Drug Trial Radar · NCT06082102
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Last checked: Nov 20, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
324
Planned (sponsor's estimate)
Start
Dec 19, 2023
Primary completion
Aug 31, 2028
Study completion Feb 25, 2030
Sponsor
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Efficacy and Safety of Orelabrutinib Combined with Rituximab versus Lenalidomide Combined with Rituximab in Patients with Relapsed/Refractory Marginal Zone Lymphoma
Conditions
- Relapsed/Refractory Marginal Zone Lymphoma
Interventions
OrelabrutinibDrug
Orelabrutinib Tablets
RituximabDrug
Rituximab Injection
LenalidomideDrug
Lenalidomide Capsules
RituximabDrug
Rituximab Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- IRC-assessed PFSTime frame: Through study completion, an average of 5 year.
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Auhui, China · Recruiting
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Guangdong Provincial Hospital of Chinese Medicine
Guangzhou, Guangdong, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Henan Provincial Peoples Hospital
Zhengzhou, Henan, China · Recruiting
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Not yet recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China · Recruiting
The Second Hospital of Dalian Medical University
Dalian, Liaoning, China · Recruiting
The first Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
The Affiliated Hospital Of Qingdao University
Qingdao, Shandong, China · Not yet recruiting
Yantai Yuhuangding Hospital
Yantai, Shandong, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
The Second Affiliated Hospital of Xi'an Jiaotong University(Xibei Hospital)
Xi’an, Shanxi, China · Recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Not yet recruiting
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.